

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – TEGLUTIK® OBTAINS DRUG REGISTRATION CERTIFICATE

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee’s Pharmaceutical Holdings Limited (the “**Company**” or “**Lee’s Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that, on 31 May 2022, the Drug Registration Certificate for Teglutik® (Riluzole Oral Suspension) has been obtained from the China National Medical Products Administration (“**NMPA**”). Teglutik® has been approved to prolong life or delay the institution of mechanical ventilation in patients with amyotrophic lateral sclerosis (“**ALS**”).

ALS is a rare disease with the prevalence of 2 to 9 per 100,000 persons and the incidence rate of 1 to 3 per 100,000 person-years. ALS results in the progressive loss of motor neurons that control voluntary muscles.

Teglutik® is licensed-in from Italfarmaco S.A. (“**Italfarmaco**”) for an exclusive distribution right to develop and commercialise the product in Mainland China, Hong Kong, Macau and Taiwan.

ABOUT TEGLUTIK®

Teglutik® (Riluzole) oral suspension is a neuroprotective agent indicated for the treatment of ALS. ALS is a fatal, adult-onset neurodegenerative disorder, which affects upper and/or lower motor neurons and is associated with degeneration of cortical and spinal motor neurons. Signs and symptoms of neurodegeneration are represented by progressive weakness of the bulbar, limb, thoracic and abdominal muscles. Cognitive dysfunction and dementia occur in 20–50% and 5–15% of cases, respectively. The disorder is one of the most common forms of Motor Neurone Disease (“**MND**”), representing more than 85% of all MND cases.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics, and has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies. More information available at www.leespharm.com.

ABOUT ITALFARMACO

ITALFARMACO is an Italian multinational based in Milan that operates in Italy and abroad in the pharmaceutical and chemical-pharmaceutical sector, with products with a high therapeutic content which mainly fall into the cardiovascular, immuno-oncological and gynecological areas. With over 80 years of history (it was founded in 1938), Italfarmaco is directly present in 30 countries, with 5 production sites and more than 3,300 employees (at group level). Italfarmaco has modern and sophisticated industrial plants where it produces medicinal specialties in pre-filled syringes, sterile preparations for injection, oral, solid and liquid products.

The mission of Italfarmaco, within the scope of business logic and fair competition, is to contribute to the improvement of quality and the prolongation of human life through the creation of pharmaceutical products and services relating to pathologies with the greatest impact on personal health, such as immuno-oncological, haemato-oncological, and rare diseases. In this context, the commitment of Italfarmaco to research and development of new and innovative drugs and industrial production according to the most demanding quality standards is significant.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 21 June 2022

As at the date of this announcement, Ms. Lee Siu Fong (Chairman) and Ms. Leelalertsuphakun Wanee are executive Directors, Dr. Li Xiaoyi and Mr. James Charles Gale are non-executive Directors, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.